Loss of antiphospholipid antibody positivity post-thrombosis in SLE

被引:18
作者
Khawaja, Muznay [1 ]
Magder, Laurence [2 ]
Goldman, Daniel [3 ]
Petri, Michelle A. [1 ]
机构
[1] Johns Hopkins Univ, Sch Med, Dept Med, Div Rheumatol, Baltimore, MD 21205 USA
[2] Univ Maryland, Med Ctr, Baltimore, MD 21201 USA
[3] Johns Hopkins Univ, Rheumatol, Baltimore, MD USA
关键词
antibodies; antiphospholipid; anticardiolipin; lupus erythematosus; systemic; SYSTEMIC-LUPUS-ERYTHEMATOSUS; INTERNATIONAL CONSENSUS STATEMENT; US COHORT LUMINA; VIPER VENOM TIME; RISK-FACTORS; ANTICARDIOLIPIN ANTIBODIES; CLASSIFICATION CRITERIA; RECURRENT THROMBOSIS; ARTERIAL THROMBOSIS; CLINICAL-COURSE;
D O I
10.1136/lupus-2020-000423
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background/Purpose Loss of positivity of antiphospholipid antibodies has been observed in clinical practice post-thrombosis in patients with SLE with secondary antiphospholipid syndrome (APS). Our study defined the frequency of this loss and the duration before positivity recurred. Methods In this prospective study, patients with SLE having at least two positive antiphospholipid markers prior to thrombosis and at least 1 year of follow-up after thrombosis were included. Antiphospholipid markers included lupus anticoagulant (dilute Russell viper venom test >45 s followed by mixing and confirmatory tests) and/or anticardiolipin titre (aCL IgG >= 20, aCL IgM >= 20 and/or aCL IgA >= 20). The percentage of visits with positive antiphospholipid markers after thrombosis was calculated. For patients with a negative antiphospholipid marker any time after thrombosis, survival estimates were performed to calculate the time to return of antiphospholipid positivity. Results In APS due to SLE, complete loss of antiphospholipid positivity post-thrombosis was up to 41% for aCL IgG, 51% for IgM and 50% for IgA, but only 20% for those with lupus anticoagulant. Of those who at some point lost aCL IgG or became negative for lupus anticoagulant, the majority (60% and 76%, respectively) reacquired the antibody within 5 years. In contrast, of those who lost aCL IgM or IgA, fewer reacquired it within 5 years (37% and 17%, respectively). Conclusion Intermittent positivity of antiphospholipid antibodies is present in APS due to SLE. These fluctuations make it difficult to decide on length of anticoagulation. Lupus anticoagulant is more likely to persist post-thrombosis.
引用
收藏
页数:7
相关论文
共 60 条
[51]  
Somers E, 2002, J RHEUMATOL, V29, P2531
[52]   SPECIAL ARTICLE - THE 1982 REVISED CRITERIA FOR THE CLASSIFICATION OF SYSTEMIC LUPUS-ERYTHEMATOSUS [J].
TAN, EM ;
COHEN, AS ;
FRIES, JF ;
MASI, AT ;
MCSHANE, DJ ;
ROTHFIELD, NF ;
SCHALLER, JG ;
TALAL, N ;
WINCHESTER, RJ .
ARTHRITIS AND RHEUMATISM, 1982, 25 (11) :1271-1277
[53]   Clinical thrombotic manifestations in SLE patients with and without antiphospholipid antibodies: A 5-year follow-up [J].
Tarr, Tunde ;
Lakos, Gabriella ;
Bhattoa, Harjit Pal ;
Soltesz, Pal ;
Shoenfeld, Yehuda ;
Szegedi, Gyula ;
Kiss, Ernese .
CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY, 2007, 32 (02) :131-137
[54]   Clinical significance and correlations between anti-β2 glycoprotein I IgA assays in antiphospholipid syndrome and/or systemic lupus erythematosus [J].
Tebo, Anne E. ;
Willis, Rohan ;
Jaskowski, Troy D. ;
Guerra, Marta ;
Pierangeli, Silvia S. ;
Salmon, Jane ;
Petri, Michelle ;
Branch, D. Ware .
CLINICA CHIMICA ACTA, 2016, 460 :107-113
[55]   Risk Factors for Thrombosis and Primary Thrombosis Prevention in Patients With Systemic Lupus Erythematosus With or Without Antiphospholipid Antibodies [J].
Tektonidou, Maria G. ;
Laskari, Katerina ;
Panagiotakos, Demosthenes B. ;
Moutsopoulos, Haralampos M. .
ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH, 2009, 61 (01) :29-36
[56]   Systemic lupus erythematosus in a multiethnic US cohort (LUMINA) -: XXIII.: Baseline predictors of vascular events [J].
Toloza, SMA ;
Uribe, AG ;
McGwin, G ;
Alarcón, GS ;
Fessler, BJ ;
Bastian, HM ;
Vilá, LM ;
Wu, RH ;
Shoenfeld, Y ;
Roseman, JM ;
Reveille, JD .
ARTHRITIS AND RHEUMATISM, 2004, 50 (12) :3947-3957
[57]   COMPARISON OF THE PRIMARY AND SECONDARY ANTIPHOSPHOLIPID SYNDROME - A EUROPEAN MULTICENTER STUDY OF 114 PATIENTS [J].
VIANNA, JL ;
KHAMASHTA, MA ;
ORDIROS, J ;
FONT, J ;
CERVERA, R ;
LOPEZSOTO, A ;
TOLOSA, C ;
FRANZ, J ;
SELVA, A ;
INGELMO, M ;
VILARDELL, M ;
HUGHES, GRV .
AMERICAN JOURNAL OF MEDICINE, 1994, 96 (01) :3-9
[58]   Risk for venous thrombosis related to antiphospholipid antibodies in systemic lupus erythematosus - A meta-analysis [J].
Wahl, DG ;
Guillemin, F ;
deMaistre, E ;
Perret, C ;
Lecompte, T ;
Thibaut, G .
LUPUS, 1997, 6 (05) :467-473
[59]  
Wilson WA, 1999, ARTHRITIS RHEUM, V42, P1309, DOI 10.1002/1529-0131(199907)42:7<1309::AID-ANR1>3.0.CO
[60]  
2-F